cyrilzakka/clinical-trials huggingface dataset:
The EFFICIENCY of FASCIAL PLANE BLOCKS in BARIATRIC SURGERY

Bariatric surgery effectively produces weight loss and reduces obesity-related comorbidities. Although it is mostly performed with minimally invasive techniques, the patients may still suffer from moderate-to-severe pain immediately after surgery \[1\]. Opioids remain the first choice for multimodal analgesia in the treatment of postoperative pain. Providing analgesia after bariatric surgery might be challenging due to a high prevalence of obstructive sleep apnea syndrome and the increased sensitivity to respiratory depression triggered by opioid overuse after surgeryThe most common plane block techniques utilized during laparoscopic bariatric surgery are transversus abdominis plane block (TAP), rectus sheath block (RB), the erector spinae plane block (ESPB) and the external oblique intercostal block (EOI). In this study, we have evaluated the auxiliary benefit of these various techniques in reduction of the postoperative in bariatric surgery. patients who had laparoscopic bariatric surgery at VKV American Hospital between January 2019 and December 2021 were reviewed retrospectively.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective bariatric surgery

Exclusion Criteria:

* Patients with a history of cerebrovascular events
* Alzheimer's and dementia
* inadequate cognitive functions
* history of chronic pain
* long-term opioid therapy
Mechanisms of Type 1 Diabetes Endophenotypes

The goal of this observational study consists of performing cluster analysis to decipher underlying disease mechanisms of type 1 diabetes in children and young adults.

To this end, we will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of children and young adults with type 1 diabetes. We will also assess the risk for cardiovascular diseases in this most vulnerable diabetes cohort.


Eligibility Criteria:
Inclusion Criteria (Type 1 Diabetic patients):

* Informed consent as documented by signature
* Patient's age: between 0 and 25 years old.
* Children, adolescents, and young adult patients followed in diabetology.

Exclusion Criteria (Type 1 Diabetic patients):

* No exclusion criteria

Inclusion Criteria (Controls):

* Informed consent as documented by signature
* Patient's age: 25 less than 6 years of age and 25 between 6 and 25 years old.
* Healthy patient

Exclusion Criteria (Controls):

* Patient receiving treatment affecting metabolic control (ex: systemic corticoids, beta blocker, immunotherapy etc.)
* Concomitant disease that may affect the analysis of the results (ex: cancer, active autoimmune disease requiring treatment)
Mass Continous Suture With PDS Versus Interrupted Suture With Thread on Major Abdominal Incision

A better suture technology will reduce postoperative incision complications. This study is designed to compare mass continous suture with PDS and interrupted suture with thread on major abdominal incision.

A better suture technology will reduce postoperative incision complications. The previous retrospective cohort study from the investigator has demonstrated that continuous mass suture with PDS led to shorter incision closure time, early wound healing and comparable incisional complications versus interrupted thread suture. As such, the current RCT study will include 100 subjects with major abdominal incision. They will be divided into two groups randomly: Mass suture gorup, mass continuous suture with PDS, Control group, interrupted suture with thread. The wound healing time, stitches removal time and incidence of incision complications will be compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* the patient with major abdominal incision.
* the incision is longer than 10 cm
* aged between 18 to 65 years old

Exclusion Criteria:

* Pregnant woman
* Patient with diabetes
* Patient with a history of cardiovascular disease, including coronary heart disease and stroke.
* Severe lung diseases such as COPD and asthma
* Patients undergoing emergent or infectious surgery
* Patients with surgical site infection
* No autonomy, inability or unwillingness to participate in follow-up
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regime.

Primary

1. Determine the clinical responses(objective response, progression-free survival, and overall survival) in patients with renal cell carcinoma treated with autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) in combination with Cytokine-Induced Killer Cell (CIK).

Secondary

1. Determine cellular immune response response in terms of immuknow assay, and correlate immune response with objective clinical response in patients treated with this regimen.
2. Determine safety of multiple administrations of this regimens in these patients.

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven renal cell carcinoma
* Age: \> 18
* WHO- ECOG Performance Status 0-1
* At least one measurable tumor lesions according to the RECIST criteria.
* Life expectancy more than 3 months
* Written informed consent

Exclusion Criteria:

* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin).
* Patients with metastatic disease in the central nervous system (CNS).
* Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.
* Patients with acute or chronic infection including HIV.
* Patients who are pregnant or nursing.
* Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.
* Patients who receive corticosteroids or other immunosuppressive agents.
* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.
Impact of Moderate Preterm Birth on Vocabulary Acquisition

Children born prematurely may present a neurodevelopmental disorder with a language delay diagnosed as early as 2-3 years of age. This situation is not uncommon: each year in France, approximately 35,000 children are born between 32 and 36 weeks of amenorrhea.

In our most recent work, we have shown that moderate premature infants show an attenuated cortical response to a vowel change, suggesting a deficit in the cortical encoding of vowels. This work needs to be continued in order to better understand syllable encoding and identify the neuroplasticity mechanisms underlying early speech encoding.

The identification of markers to predict language development is essential for the screening of these children at risk of language delay. These children could thus benefit from early adapted care even before the appearance of language deficits.


Eligibility Criteria:
Inclusion Criteria:

* Infants born prematurely (32-36 weeks gestational age, GA) or at term (40-2 weeks gestational age, GA)
* Birth weight appropriate to gestational age determined by WHO growth charts (weight, height, head circumference)
* Normal clinical examination at inclusion.
* Written informed consent obtained from both parents (or single parent if single parent)
* Infant with at least one parent who speaks and understands fluent French
* Infant is affiliated with the social security system
* Infant whose parents reside in Marseille

Exclusion Criteria:

* Neonatal distress (Apgar score \< 7)
* Hypoxic and ischemic encephalopathy
* Perinatal acidosis
* Intrauterine growth retardation
* Brain injury (such as intraventricular or periventricular hemorrhage, periventricular leukomalacia)
* Cerebral congenital malformations
* Neonatal epilepsy
* Any condition that in the opinion of the investigator would not be compatible with the conduct of this study
* Abnormal hearing test performed as part of the child's routine care at birth,
Comparative Effects of Alexander Techniques and Feldenkrais Method in Parkinson's Disease

Parkinson's disease (PD) is a neurodegenerative disorder characterized by tremors, rigidity, and postural instability. These symptoms significantly impact balance and increase the risk of falls, which subsequently lead to a heightened fear of falling and a diminished quality of life. Alexander Technique and the Feldenkrais Method have shown effects in improving overall well-being.

The study is randomized clinical trial will be carried at General hospital. 46 participants meeting the inclusion criteria will be included in this study. Participants will be randomly assigned into 2 groups, Group A and Group B participants will receive Alexander techniques and Feldenkrais method, respectively. All the groups will receive interventions for three days a week for 8 weeks.

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. These symptoms significantly impact balance and increase the risk of falls, which subsequently lead to a heightened fear of falling and a diminished quality of life. Alexander Technique and the Feldenkrais Method have shown promise in improving motor function and overall well-being. The primary objective of this study is to compare the effects of the Alexander Technique and the Feldenkrais Method on balance, fear of falling, and quality of life in patients with Parkinson's disease.

This randomized clinical trial will be carried at General hospital after the approval of permission letter. Total number of 46 participants meeting the inclusion criteria will be included in this study through a non-probability convenient sampling technique. Participants will be randomly assigned into 2 groups using computer generated randomization method. Group A and Group B participants will receive Alexander techniques and Feldenkrais method, respectively. All the groups will receive interventions for three days a week for 8 weeks. Total treatment time will be 40 minutes. The outcome measuring scales used will be Berg balance scale and time-up and go to measure balance, fall efficacy scale-international to measure fear of fall, and the Parkinson's disease questionnaire (PDQ-39) to measure quality of life. The data will be collected at baseline and after 8 weeks of therapy, to measure the outcome measures.

Eligibility Criteria:
Inclusion Criteria:

* The age group of 50 to 70 years will be included.
* Both genders (male and female)
* Patients diagnosed with Parkinson's disease of Hoehn and Yahr stage (1-3).
* Patient should be able to stand 10 minutes at least without assistance.
* Patients should be able to walk with or without assistance.
* MMSE (score higher than 24).

Exclusion Criteria:

* Recent surgery or any fracture
* Visual and hearing impairments.
* CVS impairments that interfered with therapy
* Joint pain or musculoskeletal problem that interfered with therapy
Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries

The primary goal of this study is to evaluate refractive and visual outcomes in glaucoma patients who will be having either traditional glaucoma surgery or minimally invasive glaucoma surgery, also known as MIGS.

There is an increasing number of surgical options to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension performed with or without concurrent cataract surgery. Today, patients undergoing glaucoma surgery have increasingly higher expectations for their postoperative visual outcomes. Therefore, it is important to understand the influence of various glaucoma surgical procedures on refractive outcomes. This information would aid in patient and surgical procedure selection, pre-operative counseling to set appropriate expectations and may help surgeons adjust their plans and techniques to improve visual outcomes.

The advent of minimally invasive glaucoma surgery (MIGS) procedures further highlights the importance of studying refractive outcomes as many of these surgeries are being performed earlier in the glaucoma severity spectrum where central visual potential is still preserved. Furthermore, this class of surgeries is often performed in combination with cataract surgery.

There remains a lack of data regarding refractive outcomes in patients who have had phaco-iStent, phaco-Cypass, as well as goniotomy (Kahook dual blade (KDB) gonioscopy assisted transluminal trabeculotomy), and Xen gel stent implantation with or without cataract surgery. This information would help during pre-operative patient discussions and lens selection in the context of a combined procedure.

Eligibility Criteria:
Inclusion Criteria:

Diagnosis of glaucoma or ocular hypertension in the study eye(s) and are consented to receive any of the following procedures:

* Ab interno goniotomy surgery: Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
* Gelatin stent surgery: Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
* Suprachoroidal stent and cataract surgery: Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
* Trabeculectomy surgery: Glaucoma filtering surgery to decrease intraocular pressure.
* Cataract surgery: Cataract surgery with no glaucoma procedure.

Exclusion Criteria:

Patients with previous corneal ectasia or history of refractive procedures; patients who cannot fixate well due to poor vision (worse than 20/200)
Testing the Reliability and Validity of the CIBA

The overall objective of the study is to improve the experience for pediatric patients undergoing anesthesia inductions. The specific objective for this proposal is to establish whether the CIBA tool demonstrates inter-rater reliability and concurrent validity with the Induction Compliance Checklist.

The proposed research study will assess the reliability and validity of a new tool that is being used in the Department of Anesthesia (The Child Induction Behavioral Assessment tool) to grade the difficulty of patient behaviors exhibited during anesthesia inductions. The Child Induction Behavioral Assessment (CIBA) tool is more succinct than previously validated tools for assessing behavioral responses to inhalation inductions, making it practical for use in a busy clinical practice setting. Having clinicians document a patient's behavioral response to induction using the CIBA tool is useful because this information can help to optimize subsequent induction plans if the patient returns. Additionally, population data may be collected using electronic data reports for QI purposes. Prior to using data from the CIBA tool in QI initiatives, it is important to assess whether this tool is reliable and valid.

Eligibility Criteria:
Inclusion Criteria:

* Presenting to Same Day Surgery department at CCHMC base campus for any surgical or Intervention Radiology procedure
* Ages 1-13 years old
* Male or female
* Patients of any ethnicity
* Family and participant communicate primarily in English
* Patients with normal neurocognitive development
* Patients undergoing inhalation induction using an anesthesia mask
* American Society of Anesthesiologists (ASA) physical classification status I, II, or III
* Patients who do or do not receive a premedication for anxiety
* Parent/guardian present at the induction of anesthesia

Exclusion Criteria:

* Guardian unavailable to give consent
* Neurocognitive delays
* Tracheostomy
* Intravenous (IV) induction or nitrous sedation prior to IV induction
* Coordinators unable to observe or fully observe the induction
* CIBA assessment not completed by anesthesia provider
Radiographic and Histological Evaluation of Regenerated Bone After Grafting Using Allograft Shell and Autogenous Chips

The clinical cases in the present study described the khoury shell technique using an allograft plate and autogenous chips, for horizontal reconstruction of the anterior alveolar ridge in the esthetic zone. Without need to use autogenous bone graft techniques that are characterized by more aggressive surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients with class IV of Cawood and Howell classification in the anterior maxilla.
* Males and females 18-50 years of age.
* Patients with adequate oral hygiene.
* Patients with healed sites for at least 6 months after tooth extraction.
* Patients with an inter-arch distance of at least 6 mm.
* Compliance with all requirements in the study and signing the informed consent.

Exclusion Criteria:

* Patients with diseases of the immune system or systemic disease affecting bone healing
* Patients who are chronic users of medications known to affect the periodontal status.
* Patients with history of intravenous and/or oral bisphosphonate use.
* Pathologic lesions or acute infection in the area of defect.
* Patients who are pregnant or lactating mothers.
* Heavy smokers who smoke more than 10 cigarettes a day.
* Patients with poor oral hygiene that are not amenable to motivation and improvement.
* Patients with history of irradiation of the head and neck region.
* Vulnerable patients.
Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis

This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.

Neurologists and Neuro-Ophthalmologists are in need for reliable and robust imaging biomarkers enabling to predict retinal axonal loss and visual disability after clinical episode of optic neuritis (ON). Length of optic nerve lesion measured on MRI may be one of them.

The aim of our study is to measure the association between the extent of inflammatory demyelinating process on optic nerve at the acute of ON and the retinal degenerative process following optic nerve injury.

The investigators planned to include 50 patients suffering from a recent clinical episode of ON.

Extent of demyelinating inflammatory process will be assessed by the length of optic nerve double inversion recovery (DIR) hypersignal at the acute phase of ON.

The axonal degenerative process following optic nerve demyelinating injury will be assessed by retinal atrophy measured on optical coherence tomography at 12 months after ON, by visual disability measured on low vision contrast acuity scale and by microstructural quality analysis of optic nerve measured on diffusion tensor imaging sequence of the optic nerve.

Eligibility Criteria:
Inclusion Criteria:

* patient suffering from an acute clinical episode of optic neuritis (ON) confirmed by neurophthalmological examination
* \< 2 months between start of acute episode of ON and inclusion

Exclusion Criteria:

* past history of homolateral episode of ON
* retinal diseases
* diabeta mellitus
* pregnancy
Inspired Helium for Ischemic Protection During Knee Replacement Surgery

The purpose of this study is to determine whether breathing in helium reduces indications of injury to the skeletal muscle seen in blood tests after knee replacement surgery.

The ability to reduce the risk of skeletal muscle injury may help improve patient safety by providing protection to the area of the body having its blood supply interrupted during a particular surgery.

During hospitalization, beginning the day after surgery, additional tests will be added to the daily standard of care blood samples. When daily blood samples are not ordered as part of a study participants care after surgery, blood samples only for the study tests, may be done.

Up to 60 study participants will be selected to be in one of two possible groups.

After hospital discharge the study participants physical therapist will be contacted for copies of the notes and reports about the participants progress in physical therapy. This information will be used to evaluate if the different breathing gases have any impact on how quickly people recover after surgery.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled for an elective total knee arthroplasty
* \> 18 years of age
* Expected to require inhaled oxygen concentrations \< 25%
* Able to provide informed consent

Exclusion Criteria:

* Expected to require inhaled oxygen concentrations \> 25%
* \< 18 years of age
* Member of a defined vulnerable population (e.g. pregnant, mentally handicapped, prisoners, etc.).
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL

Upon determination of eligibility, patients will receive:

* Arsenic Trioxide

Eligibility Criteria:
Inclusion Criteria:

To be included in this study, you must meet the following criteria:

* Histologically proven B-cell CLL/SLL.
* Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
* Must have progressive CLL/SLL
* Measurable or evaluable disease
* ECOG performance status 0, 1, or 2
* Age \> 18 years.
* Patients with cytopenias caused by bone marrow involvement are eligible
* All patients must give written informed consent prior to entering this study.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* Unstable active infection on the basis of neutropenia
* Previous severe opportunistic infections
* Severe immune mediated anemia or thrombocytopenia
* Serious underlying medical conditions
* Brain metastases or meningeal involvement
* History of other neoplasms
* Significant underlying heart dysfunction
* Women who are pregnant or

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.